Literature DB >> 25791800

Psoriasis and risk of diabetes-associated microvascular and macrovascular complications.

April W Armstrong1, Annie Guérin2, Murali Sundaram3, Eric Qiong Wu2, Elizabeth Sara Faust2, Raluca Ionescu-Ittu2, Parvez Mulani3.   

Abstract

BACKGROUND: Psoriasis's effect on diabetes onset is well documented, but its effect on course of diabetes is poorly understood.
OBJECTIVE: We sought to compare risks of developing microvascular and macrovascular complications between diabetic patients with and without psoriasis.
METHODS: Adults with 2 or more diabetes diagnoses selected from MarketScan databases (Truven Health Analytics Inc, Ann Arbor, MI) (2000-2006) were classified into 2 cohorts: 2 or more psoriasis diagnoses and without psoriasis diagnosis. Patients with psoriasis were matched using propensity score, and exactly matched using age, sex, and diabetes characteristics with patients without psoriasis. Outcomes were compared between cohorts using Cox regression models.
RESULTS: In all, 6164 diabetic patients with psoriasis (27% moderate to severe) were matched to 6164 diabetic patients without psoriasis. Patients with psoriasis were significantly more likely to develop microvascular events than patients without psoriasis overall (hazard ratio [HR] 1.14, P < .001) and by psoriasis severity (mild: HR 1.13, P = .004; moderate to severe: HR 1.16, P = .038). Risk of macrovascular events was higher for patients without psoriasis overall (HR 1.13, P = .001) and those with mild psoriasis (HR 1.15, P = .003), but not for moderate to severe cases (HR 1.10, P = .210). LIMITATIONS: Psoriasis to diabetes association may be underestimated.
CONCLUSION: Among diabetic patients, psoriasis is generally associated with higher rates of microvascular and macrovascular complications. Greater psoriasis severity did not increase risk of diabetic complications.
Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  complications; diabetes; inflammation; macrovascular; microvascular; observational study; psoriasis

Mesh:

Year:  2015        PMID: 25791800     DOI: 10.1016/j.jaad.2015.02.1095

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  14 in total

1.  miR-146b Probably Assists miRNA-146a in the Suppression of Keratinocyte Proliferation and Inflammatory Responses in Psoriasis.

Authors:  Helen Hermann; Toomas Runnel; Alar Aab; Hansjörg Baurecht; Elke Rodriguez; Nathaniel Magilnick; Egon Urgard; Liisi Šahmatova; Ele Prans; Julia Maslovskaja; Kristi Abram; Maire Karelson; Bret Kaldvee; Paula Reemann; Uku Haljasorg; Beate Rückert; Paulina Wawrzyniak; Michael Weichenthal; Ulrich Mrowietz; Andre Franke; Christian Gieger; Jonathan Barker; Richard Trembath; Lam C Tsoi; James T Elder; Eric R Tkaczyk; Kai Kisand; Pärt Peterson; Külli Kingo; Mark Boldin; Stephan Weidinger; Cezmi A Akdis; Ana Rebane
Journal:  J Invest Dermatol       Date:  2017-06-06       Impact factor: 8.551

2.  Histopathology of Anterior Urethral Strictures: Toward a Better Understanding of Stricture Pathophysiology.

Authors:  Matthew D Grimes; Brennan A Tesdahl; Morgan Schubbe; Lalia Dahmoush; Amy M Pearlman; Karl J Kreder; Bradley A Erickson
Journal:  J Urol       Date:  2019-09-06       Impact factor: 7.450

Review 3.  Cognitive impairment in psoriasis patients: a systematic review of case-control studies.

Authors:  Daniel Pankowski; K Wytrychiewicz-Pankowska; W Owczarek
Journal:  J Neurol       Date:  2022-08-09       Impact factor: 6.682

4.  Psoriasis, Type 2 Diabetes Mellitus, and Obesity: Weighing the Evidence.

Authors:  Joel M Gelfand
Journal:  JAMA Dermatol       Date:  2016-07-01       Impact factor: 10.282

Review 5.  Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model.

Authors:  Milena Aksentijevich; Sundus S Lateef; Paula Anzenberg; Amit K Dey; Nehal N Mehta
Journal:  Trends Cardiovasc Med       Date:  2019-11-20       Impact factor: 6.677

Review 6.  Psoriasis and comorbid diseases: Implications for management.

Authors:  Junko Takeshita; Sungat Grewal; Sinéad M Langan; Nehal N Mehta; Alexis Ogdie; Abby S Van Voorhees; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2017-03       Impact factor: 11.527

Review 7.  Psoriasis and comorbid diseases: Epidemiology.

Authors:  Junko Takeshita; Sungat Grewal; Sinéad M Langan; Nehal N Mehta; Alexis Ogdie; Abby S Van Voorhees; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2017-03       Impact factor: 11.527

Review 8.  New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies.

Authors:  Di Yan; Andrew Blauvelt; Amit K Dey; Rachel S Golpanian; Samuel T Hwang; Nehal N Mehta; Bridget Myers; Zhen-Rui Shi; Gil Yosipovitch; Stacie Bell; Wilson Liao
Journal:  J Invest Dermatol       Date:  2021-04-19       Impact factor: 7.590

Review 9.  Comorbidities in Patients with Psoriatic Arthritis.

Authors:  Amir Haddad; Devy Zisman
Journal:  Rambam Maimonides Med J       Date:  2017-01-30

Review 10.  Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis.

Authors:  Lluís Puig
Journal:  Int J Mol Sci       Date:  2017-12-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.